The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.

Including the name of the #1 company to buy.

Kenneth J. Kelley net worth and biography

Kenneth Kelley Biography and Net Worth

Director of Halozyme Therapeutics

Kenneth J. Kelley, Ph.D., is an Independent Director of the Company. Mr. Kelley brings over 35 years of entrepreneurial, venture capital, operational and technical biotechnology experience to Halozyme. He is currently Chairman of the Board and mentor to the CEOs of four privately held biotechnology companies and an advisor to various publicly held biotechnology companies. From 2016 to 2018, Mr. Kelley served as a White House Presidential Executive Fellow and a Senior Advisor to the U.S. National Institutes of Health and the National Institute of Allergy and Infectious Diseases, Vaccine Research Center and to the Assistant Secretary of Preparedness and Response. From 2015 to 2016, Mr. Kelley served as an Advanced Leadership Fellow at Harvard University working on global preparedness for epidemics and pandemics. From 2007 to 2015, Mr. Kelley served as the Chief Executive Officer of privately-held PaxVax, Inc., a specialty vaccine company acquired by Emergent BioSolutions, Inc. Previously, Mr. Kelley was a General Partner at Latterell Venture Partners, where he made investments in early stage biotechnology and medical device startups. Mr. Kelley founded IntraBiotics Pharmaceuticals in 1994 and for over eight years served as CEO, Director and Chair of the Board of Directors. Earlier, Mr. Kelley was an Associate at Institutional Venture Partners (IVP), where he participated in the financing of biotech and medical companies. Prior to IVP, he was a consultant for McKinsey & Company and a scientist at Integrated Genetics (acquired by Genzyme). Mr. Kelley earned an M.B.A. from Stanford University and a B.A. in Biochemical Sciences from Harvard University and is a Fellow in the American Institute for Medical and Biological Engineering.

What is Kenneth J. Kelley's net worth?: The estimated net worth of Kenneth J. Kelley is at least $8.44 million as of April 14th, 2021. Mr. Kelley owns 179,833 shares of Halozyme Therapeutics stock worth more than $8,444,958 as of December 22nd. This net worth estimate does not reflect any other investments that Mr. Kelley may own. Learn More about Kenneth J. Kelley's net worth.
How do I contact Kenneth J. Kelley?: The corporate mailing address for Mr. Kelley and other Halozyme Therapeutics executives is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121-1345. Halozyme Therapeutics can also be reached via phone at 858-794-8889 and via email at [email protected]. Learn More on Kenneth J. Kelley's contact information.
Has Kenneth J. Kelley been buying or selling shares of Halozyme Therapeutics?: Kenneth J. Kelley has not been actively trading shares of Halozyme Therapeutics during the last quarter. Most recently, Kenneth J. Kelley sold 5,000 shares of the business's stock in a transaction on Wednesday, April 14th. The shares were sold at an average price of $45.00, for a transaction totalling $225,000.00. Following the completion of the sale, the director now directly owns 179,833 shares of the company's stock, valued at $8,092,485. Learn More on Kenneth J. Kelley's trading history.
Who are Halozyme Therapeutics' active insiders?: Halozyme Therapeutics' insider roster includes Jean-Pierre Bizzari (Director), James Daly (Director), Jeffrey Henderson (Director), Kenneth Kelley (Director), Nicole Labrosse (CFO), Connie Matsui (Director), Matthew Posard (Director), and Helen Torley (CEO). Learn More on Halozyme Therapeutics' active insiders.
Are insiders buying or selling shares of Halozyme Therapeutics?: In the last year, insiders at the biopharmaceutical company sold shares 17 times. They sold a total of 164,881 shares worth more than $8,660,683.70. The most recent insider tranaction occured on October, 16th when SVP Michael J Labarre sold 10,000 shares worth more than $532,600.00. Insiders at Halozyme Therapeutics own 2.4% of the company. Learn More about insider trades at Halozyme Therapeutics.
Information on this page was last updated on 10/16/2024.

Kenneth J. Kelley Insider Trading History at Halozyme Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/14/2021	Sell	5,000	$45.00	$225,000.00	179,833
3/1/2021	Sell	5,000	$45.34	$226,700.00	185,333
2/1/2021	Sell	5,000	$48.12	$240,600.00	190,079
1/4/2021	Sell	5,000	$42.91	$214,550.00	195,123
12/7/2020	Sell	35,086	$41.00	$1,438,526.00	199,833
12/2/2020	Sell	31,792	$41.00	$1,303,472.00	234,919
11/27/2020	Sell	10,000	$41.25	$412,500.00	276,711
3/19/2020	Buy	52,629	$14.23	$748,910.67	242,467
6/18/2015	Sell	20,000	$21.00	$420,000.00
8/27/2012	Buy	20,000	$5.70	$114,000.00

Kenneth J. Kelley Buying and Selling Activity at Halozyme Therapeutics

Halozyme Therapeutics Company Overview

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Today's Range

Now: $46.96

$46.88

$48.21

50 Day Range

MA: $50.91

$42.57

$61.09

2 Week Range

Now: $46.96

$33.15

$65.53

Volume

4,794,681 shs

Average Volume

1,379,155 shs

Market Capitalization

$5.97 billion

P/E Ratio

15.55

Dividend Yield

N/A

Beta

1.23

Why Buffett, Griffin and 100 members of Congress are Piling into this One Investment

From Behind the Markets | Ad

This isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.

Click here for the ticker >>>